Prophylactic HIV Drugs Market Snapshot (2023 to 2033)

The anticipated size of the prophylactic HIV drugs market in 2022 was US$ 31,278.5 million and is estimated to be US$ 32,516.1 million in 2023.

Growth in the market is mainly due to an increase in research and development through investment in HIV clinical trials of pharmaceutical and biotechnology companies, increasing drug approvals for HIV, and a rise in the incidence of HIV in the population. According to Future Market Insights estimation, the market is predicted to expand at a CAGR of 4.1% between 2023 and 2033, totaling around US$ 48,822.4 million by 2033.

The global prophylactic HIV drugs market size reached a valuation of around US$ 30 billion in 2021. Due to the rising prevalence of HIV infection worldwide and growing awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs registered a 4% CAGR between 2022 and 2032, totaling over US$ 40 billion in 2028.

Human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide affecting millions of people. The virus targets the immune system of infected patients and makes them vulnerable to many infections and cancers.

The condition can be managed through increasing access to effective prevention, diagnosis, treatment, and care although there is no permanent cure available for HIV infection. The rising focus on preventing the acquisition of HIV is one of the key factors pushing the demand for prophylactic HIV drugs.

Prophylactic HIV drugs are advanced therapeutics used to prevent getting HIV infection in certain circumstances as they have been especially effective in preventing the acquisition of HIV from sex and injection drug use.

Amid the rising prevalence of HIV, people across the world are showing a keen inclination toward consuming pre-exposure prophylaxis (PrEP) due to its better effectiveness. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex and injection drug use by around 99% and 74% respectively.

Prophylactic HIV drugs such as antiretroviral (ARV) are gaining immense popularity due to their ability to prevent and control HIV infection. Additionally, growing awareness among people regarding HIV and the benefits of prophylactic HIV drugs might continue to boost the sales of prophylactic HIV drugs during the forecast period.

Attributes Details
Projected Forecast Value (2022) US$ 31,278.5 million
Projected Forecast Value (2023) US$ 32,516.1 million
Projected Forecast Value (2033) US$ 48,822.4 million
Growth rate 4.1% CAGR
Forecast period 2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Prophylactic HIV Drugs Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)

The global prophylactic drugs market expanded at a CAGR of 3.5% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 4.1% between 2023 and 2033.

Future growth of the market is estimated to boost by initiating various potential pipeline candidates like fostemsavir and PRO 140 by the drivers of generic versions of various branded drugs such as tenofovir disoproxil fumarate tablets.

Which are the Factors Stimulating Growth in the Prophylactic HIV Drugs Market?

Rise in HIV Cases Worldwide

The notable surge in HIV cases worldwide, continuous novel drug launches and approvals, and the increasing need for preventing and controlling HIV are some of the major factors stimulating the growth of the prophylactic HIV drugs market.

Prophylactic HIV drugs have become highly sought-after therapeutics for preventing the acquisition of HIV infection among people who are at high risk. Consumption of these drugs significantly reduces the chances of HIV infection. They are mostly recommended during sex and injection drug use where there is a high chance of HIV transmission.

The growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of the prophylactic HIV drugs market and the trend is likely to continue during the forecast period.

The increasing prevalence of HIV and its high mortality rate are pushing the demand for therapeutics like prophylactic HIV drugs. According to the World Health Organization (WHO), there were around 1.5 million newly infected cases of HIV and over 680000 deaths in 2020. This is prompting people to use prophylactic HIV drugs.

Increasing government initiatives and investments in spreading awareness among people about HIV, its symptoms, precautions, and treatment are expected to further expand the prophylactic HIV drug market size during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by Prophylactic HIV Drugs Market?

Side Effects Associated with Prophylactic HIV Drugs

Certain obstacles are challenging the growth of the prophylactic HIV drugs market despite its optimistic stance. Some of these obstacles include side effects associated with prophylactic HIV drugs, strict government approval for these drugs, and low awareness levels about these therapeutics across low emerging economies.

It has been observed that prophylactic HIV drugs often lead to side effects such as headache, depression, nausea, vomiting, abdominal pain, etc. Many people refrain from consuming these therapeutics. This in turn is limiting the growth of the prophylactic HIV drugs market.

Region-wise Analysis

Does North America Retain its Monopoly in the Global Prophylactic HIV Drugs Market?

Growth in North America Prophylactic HIV drugs market

According to FMI analysis, North America is likely to retain its dominant position in the global prophylactic HIV drugs market with a value share of 41.7%, accounting for a significant market share. Moreover, growth in North America's prophylactic HIV drugs market is underpinned by the presence of a high level of awareness among people, the surge in HIV infection cases, the availability of advanced healthcare facilities, and the growing adoption of new therapeutics.

Demand for prophylactic HIV drugs is especially rising across countries like the United States and Mexico due to a surge in HIV cases. The rapid surge in cases of HIV infection in the United States holds a value share of 36.9% resulting in the rising incidences of unprotected sex and the use of unsterile injections. Moreover, there were around 34800 new HIV infection cases reported in the USA. The rise in HIV infection cases is playing a key role in pushing the growth of the prophylactic HIV drugs market.

How is Prophylactic HIV Drugs Market Likely to Fare in Europe?

The Rising Prevalence of HIV Infection and Increasing Adoption of Novel Therapeutics

Amid the rising prevalence of HIV infection and increasing adoption of novel therapeutics, Europe's prophylactic HIV drugs market is likely to expand at a CAGR of 28% with a considerable pace during the forecast period.

Sharp rise in cases of HIV in countries of Europe like the United Kingdom expanding at a CAGR of 5.0%. As per the European Centre for Disease Prevention and Control, over 2.2 million people have been diagnosed and reported with HIV in the Europe Region according to WHO during the last three decades. This in turn is fostering the growth of the prophylactic HIV drugs market in the region. Further, the presence of leading manufacturers such as ViiV Health is positively impacting the growth of the prophylactic HIV drugs market across Europe.

How is the Asia Pacific Region Emerging as an Opportunistic Prophylactic HIV Drugs Market?

Introduction of Public Health Intervention for Minimization of HIV Transmission

Pre-exposure prophylaxis (PrEP) in China, is a newly introduced public health intervention for minimizing HIV transmission, where the coverage has remained limited expanding at a CAGR of 5%. Best delivery models and strategies for broadening access to vulnerable communities are not fully known.

Reviews have identified that PrEP programs reporting in India expanding at a CAGR of 4.1% were differentiated by delivery models that are accompanied by a healthcare accessibility framework.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Comparative Analysis of the Prophylactic HIV Drugs Market

Prophylactic HIV Drugs Market:

Attributes Prophylactic HIV Drugs Market
CAGR (2023 to 2033) 4.1%
Market Value 2023 US$ 32,516.1 million
Growth Factor Non-profit organizations and pharmaceutical and biotechnology companies are investing more in HIV clinical research, which in turn boosts the growth of the market.
Future Opportunities Prominent manufacturers of the drugs present in the global market are striving ardently for conducting extensive research and development activities to introduce new products.
Market trends The growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of the prophylactic HIV drugs market

HIV Drugs Market:

Attributes HIV Drugs Market
CAGR (2023 to 2033) 6.9%
Market Value 2023 US$ 34,300 million
Growth Factor Change in growth trend is mainly because the companies mainly balance their output after arranging the demand that grew exponentially.
Future Opportunities An increase in emphasis on research and development activities in the field of HIV drugs is anticipated for the results that lead to the rise in drug innovations worldwide.
Market trends A rise in awareness among people due to the diagnosis and treatment of HIV disease acts as a key driver acting as growth for the HIV drug market.

Injectable Drugs Market:

Attributes Injectable Drugs Market
CAGR (2023 to 2033) 6.2%
Market Value 2023 US$ 52,239 million
Growth Factor The increase in the burden of infectious diseases, oncology diseases, and cardiovascular diseases is raising the demand for effective treatment solutions across the globe, which is anticipated to boost sales.
Future Opportunities Significant extension in the pharmaceutical sector might fuel sales of the injectable drugs market.
Market trends The proportion of drugs in the pipeline that requires injectable administration has increased due to the rise in the production and availability of biological drugs in the global healthcare market.

Category-wise Analysis

Which Drug has a Dominant Position in the Market?

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) are Considered to have a Dominant Position in the Market

NRTIs are likely to hold a dominant position with a value share of 53.90%as it is mainly helpful if a person is pregnant or has other health conditions other than HIV.

NRTI mainly works by preventing the virus from further multiplying in the body. For example - HIV mainly, NRTIs work by blocking the reverse transcriptase, the enzyme that HIV needs to replicate itself.

Which Distribution Channel is Preferred Most in this Market?

Hospital Pharmacies are Preferred the Most in the Market

Hospital Pharmacies significantly hold a value share of 56.50% as people suffering from such a disease are likely to get cured in hospital pharmacies provided with proper treatment facilities.

Market Competition

Some of the prominent players operating in the global market are-

  • Gilead Sciences, Inc
  • Merck Sharp & Dohme Corp.
  • Merck & Co. Inc.
  • Mylan NV
  • Cipla Inc.
  • Genentech Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Health Care Systems Inc
  • Pfizer Inc.
  • GalaxoSmithKline PLC

Notable Developments of the Key Players in the Market

  • In April 2023, Merck & Co (MRK.N) confirmed that it is going to buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, by picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology.
  • In November 2022, Merck, known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, might acquire Imago for US$ 36.00 per share in cash for around total equity value of US$ 1.35 billion.

Report Scope

Report Attributes Details
Growth Rate CAGR of 4.1% from 2023 to 2033
Market value in 2023 US$ 32,516.1 million
Market value in 2033 US$ 48,822.4 million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units US$ million for Value and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • By Drug
  • By Distribution Channel
  • By Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia and Pacific
  • East Asia
  • The Middle East & Africa
Key Countries Profiled
  • TheUnited States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Poland
  • Russia
  • Czech Republic
  • Romania
  • India
  • Bangladesh
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Gilead Sciences, Inc
  • Merck Sharp & Dohme Corp.
  • Merck & Co. Inc.
  • Mylan NV
  • Cipla Inc.
  • Genentech Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Health Care Systems Inc
  • Pfizer Inc.
  • GalaxoSmithKline PLC
Customization Scope Available on Request

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey

By Drug Class:

  • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  • Integrase Inhibitor

By Distributional Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan
  • Japan
  • The Middle East and Africa

Frequently Asked Questions

What is the Current Estimated Valuation of the Prophylactic HIV Drugs Market?

The prophylactic HIV drugs market is set to attain a value of US$ 32,516.1 million in 2023.

What size is the Prophylactic HIV Drugs Market expected to reach by 2033?

The prophylactic HIV drugs market is estimated to surpass US$ 48,822.4 million by 2033.

What is the CAGR Forecast for the Prophylactic HIV Drugs Market?

The prophylactic HIV drugs market is projected to experience a CAGR of 4.1% through 2033.

Which Region Reveals Substantial Economic Advantages for Prophylactic HIV Drugs?

North America's prophylactic HIV drugs market holds substantial revenue prospects, capturing a 41.7% value share.

Which Segment Takes Precedence Based on Drug Class in the Prophylactic HIV Drugs Market?

With a commanding value share of 53.90%, the NRTI segment secures the top position in the prophylactic HIV drugs market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)

        5.3.2. Integrase Inhibitor

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distributional Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Distributional Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Mail Order Pharmacies

        6.3.4. Drug Stores

    6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distributional Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distributional Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distributional Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distributional Channel

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Drug Class

        10.2.3. By Distributional Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distributional Channel

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Drug Class

        11.2.3. By Distributional Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distributional Channel

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Drug Class

        12.2.3. By Distributional Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distributional Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Distributional Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distributional Channel

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug Class

        14.2.3. By Distributional Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distributional Channel

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. U.S.

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug Class

            15.1.2.2. By Distributional Channel

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug Class

            15.2.2.2. By Distributional Channel

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug Class

            15.3.2.2. By Distributional Channel

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug Class

            15.4.2.2. By Distributional Channel

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug Class

            15.5.2.2. By Distributional Channel

    15.6. U.K.

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug Class

            15.6.2.2. By Distributional Channel

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug Class

            15.7.2.2. By Distributional Channel

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug Class

            15.8.2.2. By Distributional Channel

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug Class

            15.9.2.2. By Distributional Channel

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug Class

            15.10.2.2. By Distributional Channel

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug Class

            15.11.2.2. By Distributional Channel

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug Class

            15.12.2.2. By Distributional Channel

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug Class

            15.13.2.2. By Distributional Channel

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug Class

            15.14.2.2. By Distributional Channel

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug Class

            15.15.2.2. By Distributional Channel

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug Class

            15.16.2.2. By Distributional Channel

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug Class

            15.17.2.2. By Distributional Channel

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug Class

            15.18.2.2. By Distributional Channel

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug Class

            15.19.2.2. By Distributional Channel

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug Class

            15.20.2.2. By Distributional Channel

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug Class

            15.21.2.2. By Distributional Channel

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Drug Class

            15.22.2.2. By Distributional Channel

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Drug Class

            15.23.2.2. By Distributional Channel

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug Class

        16.3.3. By Distributional Channel

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Gilead Sciences, Inc

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

                17.1.1.5.2. Product Strategy

                17.1.1.5.3. Channel Strategy

        17.1.2. Merck Sharp & Dohme Corp.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

                17.1.2.5.2. Product Strategy

                17.1.2.5.3. Channel Strategy

        17.1.3. Merck & Co. Inc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

                17.1.3.5.2. Product Strategy

                17.1.3.5.3. Channel Strategy

        17.1.4. Mylan NV

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

                17.1.4.5.2. Product Strategy

                17.1.4.5.3. Channel Strategy

        17.1.5. Cipla Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

                17.1.5.5.2. Product Strategy

                17.1.5.5.3. Channel Strategy

        17.1.6. Genentech Inc.

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

                17.1.6.5.2. Product Strategy

                17.1.6.5.3. Channel Strategy

        17.1.7. Bristol-Myers Squibb Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

                17.1.7.5.2. Product Strategy

                17.1.7.5.3. Channel Strategy

        17.1.8. Johnson & Johnson Health Care Systems Inc

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

                17.1.8.5.2. Product Strategy

                17.1.8.5.3. Channel Strategy

        17.1.9. Pfizer Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

                17.1.9.5.2. Product Strategy

                17.1.9.5.3. Channel Strategy

        17.1.10. GalaxoSmithKline PLC

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

                17.1.10.5.2. Product Strategy

                17.1.10.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Infection Prevention Market

September 2021

REP-GB-13950

December 2023

333 pages

Healthcare

HIV/HBV/HCV Test Kits Market

February 2022

REP-GB-9814

March 2023

304 pages

Healthcare

HIV Antivirals Market

June 2022

REP-GB-15095

300 pages

Healthcare

HIV Diagnostics Market

May 2022

REP-GB-14678

306 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Prophylactic HIV Drugs Market